Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) released its earnings results on Monday. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.05), Zacks reports.
Oric Pharmaceuticals Price Performance
Shares of Oric Pharmaceuticals stock opened at $7.52 on Tuesday. The stock’s 50 day simple moving average is $11.45 and its 200-day simple moving average is $10.99. The stock has a market cap of $779.45 million, a P/E ratio of -5.57 and a beta of 1.23. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.68.
Insider Activity at Oric Pharmaceuticals
In related news, CFO Dominic Piscitelli sold 14,000 shares of the stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total value of $189,420.00. Following the completion of the sale, the chief financial officer owned 69,828 shares of the company’s stock, valued at approximately $944,772.84. This trade represents a 16.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock valued at $1,432,952 over the last ninety days. 5.70% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Several brokerages recently commented on ORIC. BTIG Research reiterated a “buy” rating and set a $26.00 price target on shares of Oric Pharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. raised their price objective on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Wedbush lowered their target price on shares of Oric Pharmaceuticals from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 27th. Stifel Nicolaus upped their target price on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, October 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, October 15th. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $21.25.
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Read More
- Five stocks we like better than Oric Pharmaceuticals
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
